Last reviewed · How we verify
Ad26.COV2.S vaccine
Ad26.COV2.S vaccine is a viral vector vaccine Biologic drug developed by University Medical Center Groningen. It is currently FDA-approved for COVID-19 prevention in adults.
Ad26.COV2.S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.
Ad26.COV2.S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults.
At a glance
| Generic name | Ad26.COV2.S vaccine |
|---|---|
| Sponsor | University Medical Center Groningen |
| Drug class | viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine uses a replication-incompetent adenovirus serotype 26 (Ad26) as a vector to introduce genetic instructions for producing the SARS-CoV-2 spike protein. This triggers both cellular and humoral immune responses, enabling the body to recognize and neutralize the virus upon exposure. The single-dose formulation provides protection against COVID-19 infection and severe disease.
Approved indications
- COVID-19 prevention in adults
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients (PHASE3)
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders (PHASE2)
- Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
- A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults (PHASE3)
- A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (PHASE2)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.COV2.S vaccine CI brief — competitive landscape report
- Ad26.COV2.S vaccine updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI
Frequently asked questions about Ad26.COV2.S vaccine
What is Ad26.COV2.S vaccine?
How does Ad26.COV2.S vaccine work?
What is Ad26.COV2.S vaccine used for?
Who makes Ad26.COV2.S vaccine?
What drug class is Ad26.COV2.S vaccine in?
What development phase is Ad26.COV2.S vaccine in?
What are the side effects of Ad26.COV2.S vaccine?
What does Ad26.COV2.S vaccine target?
Related
- Drug class: All viral vector vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: University Medical Center Groningen — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention in adults
- Compare: Ad26.COV2.S vaccine vs similar drugs
- Pricing: Ad26.COV2.S vaccine cost, discount & access